Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats
- PMID: 10554102
- DOI: 10.1023/a:1018912806355
Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats
Abstract
Purpose: The purpose of this study was to determine the effects of disopyramide and verapamil on the renal handling of cisplatin (CDDP) and nephrotoxicity in rats. The stereoselective effect of verapamil was also studied.
Methods: CDDP was administered to rats by i.v. bolus injection or by infusion at a constant rate with or without concomitant administration of racemic disopyramide, racemic verapamil, or each verapamil enantiomer. The concentrations of CDDP in plasma and in the kidney and liver were determined by HPLC. In separate experiments, CDDP was administered as described above, and blood urea nitrogen (BUN) was monitored for 7 days.
Results: The BUN level after administration of CDDP was significantly reduced by coadministration of either disopyramide or verapamil. Renal accumulation of CDDP was significantly reduced by these drugs, whereas accumulation into the liver was not significantly changed. The relationship between the BUN levels and the area under the curve of CDDP concentration in the kidney versus time (AUCk) was analyzed using a sigmoid Emax model; this showed that the reduced BUN levels were explained by the AUCk. Furthermore, verapamil showed stereoselective inhibition of the renal accumulation of CDDP.
Conclusions: The renal accumulation of CDDP was inhibited by disopyramide and verapamil, and this inhibition resulted in the amelioration of nephrotoxicity.
Similar articles
-
Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.Arch Toxicol. 2000 Aug;74(6):300-7. doi: 10.1007/s002040000124. Arch Toxicol. 2000. PMID: 11005675
-
Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.Cancer Chemother Pharmacol. 1997;40(1):11-8. doi: 10.1007/s002800050618. Cancer Chemother Pharmacol. 1997. PMID: 9137523
-
Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.J Pharm Pharmacol. 2000 Nov;52(11):1345-53. doi: 10.1211/0022357001777496. J Pharm Pharmacol. 2000. PMID: 11186242
-
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.J Biomed Sci. 2019 Mar 13;26(1):25. doi: 10.1186/s12929-019-0518-9. J Biomed Sci. 2019. PMID: 30866950 Free PMC article. Review.
-
Mechanisms of Cisplatin nephrotoxicity.Toxins (Basel). 2010 Nov;2(11):2490-518. doi: 10.3390/toxins2112490. Epub 2010 Oct 26. Toxins (Basel). 2010. PMID: 22069563 Free PMC article. Review.
Cited by
-
Modulating the Activity of the Human Organic Cation Transporter 2 Emerges as a Potential Strategy to Mitigate Unwanted Toxicities Associated with Cisplatin Chemotherapy.Int J Mol Sci. 2024 Mar 2;25(5):2922. doi: 10.3390/ijms25052922. Int J Mol Sci. 2024. PMID: 38474165 Free PMC article.
-
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.Am J Pathol. 2005 Dec;167(6):1477-84. doi: 10.1016/S0002-9440(10)61234-5. Am J Pathol. 2005. PMID: 16314463 Free PMC article.
-
Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.Pharm Res. 2010 Sep;27(9):1893-9. doi: 10.1007/s11095-010-0189-4. Epub 2010 Jun 15. Pharm Res. 2010. PMID: 20552253
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical